The medical management of peyronie's disease

ABSTRACT There are a wide variety of medical treatments that are available to the practicing urologist, including oral agents, topical creams and gels with or without iontophoresis,

intralesional injection therapy, radiation therapy, extracorporeal shockwave therapy, and laser therapy. Medical management of Peyronie's disease might be a valuable treatment option

for this debilitating disorder, especially in the early symptomatic stages of the disease. Although no single modality has been demonstrated to have superior efficacy, intralesional therapy

appears to confer some benefit. Multicenter, large-scale, randomized, controlled studies are necessary to fully establish the efficacy of the available treatments. Until such trials are

conducted, a rational approach involving combination therapy is the most appropriate method to treat these patients. In this Review, the current medical treatment options available for the

management of Peyronie's disease are discussed and a management algorithm is proposed. KEY POINTS * Peyronie's disease is a disorder of the penis occurring in men over 40 years of

age, and is clinically associated with penile pain in the flaccid or erect state, penile deviation, penile plaques, and erectile dysfunction * The aim of medical therapy is to treat and

alleviate the morbidity associated with this disease * The etiology is poorly understood, and this might account for the questionable efficacy of some current medical therapies * Several

mechanisms have been postulated as the cause in susceptible individuals, including trauma, collagen deposition, aberrant wound healing, and fibrosis * Agents that have been shown in

well-designed, randomized, placebo-controlled trials to have an effect in Peyronie's disease include intralesional verapamil, colchicine, and possibly intralesional interferon Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices

may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support

SIMILAR CONTENT BEING VIEWED BY OTHERS A SYSTEMATIC REVIEW OF NON-SURGICAL MANAGEMENT IN PEYRONIEʼS DISEASE Article Open access 26 October 2022 LOW-INTENSITY SHOCKWAVE THERAPY IN PEYRONIE’S

DISEASE: LONG-TERM RESULTS FROM A PROSPECTIVE, RANDOMIZED, SHAM-CONTROLLED TRIAL Article 18 May 2021 COMPARISON OF THE EFFICACY AND ADVERSE EFFECTS OF LONG PULSED 1064 NM ND: YAG LASER AND

SCLEROTHERAPY IN THE TREATMENT OF PYOGENIC GRANULOMA IN CHILDREN: A RETROSPECTIVE STUDY Article Open access 22 January 2025 REFERENCES * Hellstrom WJ and Bivalacqua TJ (2000) Peyronie's

disease: etiology, medical, and surgical therapy. _J Androl_ 21: 347–354 CAS  PubMed  Google Scholar  * Carson CC (1981) Francois Gigot de la Peyronie (1678–1747). _Invest Urol_ 19: 62–63

CAS  PubMed  Google Scholar  * de la Peyronie F (1743) Sur quelque obstacles qui s'opposent a l'ejaculation naturelle de la semence. _Mem Acad Chir_ 1: 318 Google Scholar  *

Schwarzer U _ et al_. (2001) The prevalence of Peyronie's disease: results of a large survey. _BJU Int_ 88: 727–730 Article  CAS  Google Scholar  * Kadioglu A _ et al_. (2002) A

retrospective review of 307 men with Peyronie's disease. _J Urol_ 168: 1075–1079 Article  Google Scholar  * Mulhall JP _ et al_. (2004) Subjective and objective analysis of the

prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. _J Urol_ 171: 2350–2353 Article  Google Scholar  * Mulhall JP _ et al_. (2003)

Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. _J Urol_ 170: 281–284 Article  CAS  Google Scholar  * Lindsay MB _ et al_. (1991) The incidence of

Peyronie's disease in Rochester, Minnesota, 1950 through 1984. _J Urol_ 146: 1007–1009 Article  CAS  Google Scholar  * Sommer F _ et al_. (2002) Epidemiology of Peyronie's disease.

_Int J Impot Res_ 14: 379–383 Article  CAS  Google Scholar  * Rhoden EL _ et al_. (2001) Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil. _Int J Impot Res_

13: 291–293 Article  CAS  Google Scholar  * Devine CJ Jr _ et al_. (1997) Proposal: trauma as the cause of the Peyronie's lesion. _J Urol_ 157: 285–290 Article  Google Scholar  * Somers

KD and Dawson DM (1997) Fibrin deposition in Peyronie's disease plaque. _J Urol_ 157: 311–315 Article  CAS  Google Scholar  * Schiavino D _ et al_. (1997) Immunologic findings in

Peyronie's disease: a controlled study. _Urology_ 50: 764–768 Article  CAS  Google Scholar  * Chilton CP _ et al_. (1982) Factors associated in the aetiology of Peyronie's disease.

_Br J Urol_ 54: 748–750 Article  CAS  Google Scholar  * Gelbard MK _ et al_. (1990) The natural history of Peyronie's disease. _J Urol_ 144: 1376–1379 Article  CAS  Google Scholar  *

Furlow WL _ et al_. (1975) Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. _J Urol_ 114: 69–71 Article  CAS  Google Scholar  * Williams

JL and Thomas GG (1970) The natural history of Peyronie's disease. _J Urol_ 103: 75–76 Article  CAS  Google Scholar  * Scardino PL and Scott WW (1949) The use of tocopherols in the

treatment of Peyronie's disease. _Ann NY Acad Sci_ 52: 390–401 Article  Google Scholar  * Prieto Castro RM _ et al_. (2003) Combined treatment with vitamin E and colchicine in the early

stages of Peyronie's disease. _BJU Int_ 91: 522–524 Article  CAS  Google Scholar  * Mynderse LA and Monga M (2002) Oral therapy for Peyronie's disease. _Int J Impot Res_ 14:

340–344 Article  CAS  Google Scholar  * Pryor JP and Farrell CR (1983) Controlled clinical trial of vitamin E in Peyronie's disease. _Prog Reprod Biol Med_ 9: 61–67 Google Scholar  *

Zarafonetis CJ and Horrax TM (1959) Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). _J Urol_ 81: 770–772 Article  CAS  Google Scholar  * Weidner W (1999)

Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). _J Urol_ 6 (Suppl): S205 Article  Google Scholar  * Shah PJR _ et

al_. (1983) A multicentre double blind controlled clinical trial of potassium paraminobenzoate (Potaba) in Peyronie's disease. _Prog Reprod Biol Med_ 9: 61–67 Google Scholar  * Akkus E

_ et al_. (1994) Is colchicine effective in Peyronie's disease? A pilot study. _Urology_ 44: 291–295 Article  CAS  Google Scholar  * Kadioglu A _ et al_. (2000) Treatment of

Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. _Int J Impot Res_ 12: 169–175 Article  CAS  Google Scholar  * Safarinejad MR

(2004) Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. _Int J Impot Res_ 16: 238–243 Article  CAS  Google

Scholar  * Ralph DJ _ et al_. (1992) The treatment of Peyronie's disease with tamoxifen. _Br J Urol_ 70: 648–651 Article  CAS  Google Scholar  * Teloken C _ et al_. (1999) Tamoxifen

versus placebo in the treatment of Peyronie's disease. _J Urol_ 162: 2003–2005 Article  CAS  Google Scholar  * Biagiotti G and Cavallini G (2001) Acetyl-L-carnitine vs tamoxifen in the

oral therapy of Peyronie's disease: a preliminary report. _BJU Int_ 88: 63–67 Article  CAS  Google Scholar  * Cavallini G _ et al_. (2002) Oral propionyl-l-carnitine and intraplaque

verapamil in the therapy of advanced and resistant Peyronie's disease. _BJU Int_ 89: 895–900 Article  CAS  Google Scholar  * Fitch WP and Easterling WJ (2002) Topical verapamil,

trifluopexane and magnesium sulphate for Peyronie's disease [abstract]. _J Urol_ 167: a205 Google Scholar  * Martin DJ _ et al_. (2002) Transdermal application of verapamil gel to the

penile shaft fails to infiltrate the tunica albuginea. _J Urol_ 168: 2483–2485 Article  CAS  Google Scholar  * Rothfeld SH and Murray W (1967) The treatment of Peyronie's disease by

iontophoresis of C21 esterified glucocortocoids. _J Urol_ 97: 874–875 Article  CAS  Google Scholar  * Montorsi F _ et al_. (2000) Transdermal electromotive multi-drug administration for

Peyronie's disease: preliminary results. _J Androl_ 21: 85–90 CAS  PubMed  Google Scholar  * Riedl CR _ et al_. (2000) Iontophoresis for treatment of Peyronie's disease. _J Urol_

163: 95–99 Article  CAS  Google Scholar  * Levine LA _ et al_. (2003) Tunica albuginea tissue analysis after electromotive drug administration. _J Urol_ 169: 1775–1778 Article  CAS  Google

Scholar  * Di Stasi SM _ et al_. (2004) A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. _J Urol_

171: 1605–1608 Article  CAS  Google Scholar  * Gelbard MK _ et al_. (1982) Collagenase for Peyronie's disease experimental studies. _Urol Res_ 10: 135–140 Article  CAS  Google Scholar 

* Gelbard MK _ et al_. (1985) The use of collagenase in the treatment of Peyronie's disease. _J Urol_ 134: 280–283 Article  CAS  Google Scholar  * Gelbard MK _ et al_. (1993)

Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. _J Urol_ 149: 56–58 Article  CAS  Google Scholar  * Kelly RB (1985) Pathways of protein

secretion in eukaryotes. _Science_ 230: 25–32 Article  CAS  Google Scholar  * Lee RC and Ping JA (1990) Calcium antagonists retard extracellular matrix production in connective tissue

equivalent. _J Surg Res_ 49: 463–466 Article  CAS  Google Scholar  * Lee RC _ et al_. (1994) The response of burn scars to intralesional verapamil. Report of five cases. _Arch Surg_ 129:

107–111 Article  CAS  Google Scholar  * Levine LA _ et al_. (1994) Intralesional verapamil injection for the treatment of Peyronie's disease. _J Urol_ 151: 1522–1524 Article  CAS 

Google Scholar  * Levine LA _ et al_. (2002) Experience with intraplaque injection of verapamil for Peyronie's disease. _J Urol_ 168: 621–625 Article  CAS  Google Scholar  * Bodner H _

et al_. (1953) Peyronie's disease; cortisone-hyaluronidase-hydrocortisone therapy. _Trans West Sect Am Urol Assoc_ 20: 32–35 CAS  PubMed  Google Scholar  * Winter CC and Khanna R (1975)

Peyronie's disease: results with dermo-jet injection of dexamethasone. _J Urol_ 114: 898–900 Article  CAS  Google Scholar  * Williams G and Green NA (1980) The non-surgical treatment

of Peyronie's disease. _Br J Urol_ 52: 392–395 Article  CAS  Google Scholar  * Lamprakopoulos A _ et al_. (2000) The use of betamethasone and hyaluronidase injections in the treatment

of Peyronie's disease. _Scand J Urol Nephrol_ 34: 355–360 Article  CAS  Google Scholar  * Duncan MR _ et al_. (1991) Regulation of the proliferation and biosynthetic activities of

cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. _Scand J Urol Nephrol_ 25: 89–94 Article  CAS  Google Scholar  * Brake M _ et al_. (2001) Treatment

of Peyronie's disease with local interferon-alpha 2b. _BJU Int_ 87: 654–657 Article  CAS  Google Scholar  * Hellstrom WJ _ et al_. (2006) Single-blind, multicenter, placebo controlled,

parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. _J Urol_ 176: 394–398 Article  CAS 

Google Scholar  * Abdel-Salam Y _ et al_. (1999) Treatment of Peyronie's disease by extracorporeal shockwave therapy: evaluation of our preliminary results. _J Endourol_ 13: 549–552

Article  CAS  Google Scholar  * Husain J _ et al_. (2000) Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. _BJU Int_ 86: 466–468 Article 

CAS  Google Scholar  * Manikandan R _ et al_. (2002) Evaluation of extracorporeal shock wave therapy in Peyronie's disease. _Urology_ 60: 795–759 Article  CAS  Google Scholar  * Lebret

T _ et al_. (2002) Extracorporeal shock wave therapy in the treatment of Peyronie's disease: experience with standard lithotriptor (siemens-multiline). _Urology_ 59: 657–661 Article 

Google Scholar  * Hauck EW _ et al_. (2000) Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case–controlled approach. _Eur Urol_ 38: 663–669

Article  CAS  Google Scholar  * Levine LA (2003) Review of current nonsurgical management of Peyronie's disease. _Int J Impot Res_ 15 (Suppl 5): S113–S120 Article  Google Scholar  *

Hauck EW _ et al_. (2004) Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. _J Urol_ 171: 740–745 Article  Google Scholar  *

Rodrigues CI _ et al_. (1995) Results of radiotherapy and vitamin E in the treatment of Peyronie's disease. _Int J Radiat Oncol Biol Phys_ 31: 571–576 Article  CAS  Google Scholar  *

Incrocci L _ et al_. (2000) Current sexual functioning in 106 patients with Peyronie's disease treated with radiotherapy 9 years earlier. _Urology_ 56: 1030–1034 Article  CAS  Google

Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Y Akin-Olugbade is a Fellow and JP Mulhall is an Associate Professor in the Department of Urology at Weill Medical

College of Cornell University, New York Presbyterian Hospital, New York, NY, USA., Yemi Akin-Olugbade & John P Mulhall Authors * Yemi Akin-Olugbade View author publications You can also

search for this author inPubMed Google Scholar * John P Mulhall View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to

John P Mulhall. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Akin-Olugbade, Y., Mulhall, J. The medical management of Peyronie's disease. _Nat Rev Urol_ 4, 95–103 (2007). https://doi.org/10.1038/ncpuro0729 Download citation * Received: 06

April 2005 * Accepted: 08 December 2006 * Issue Date: February 2007 * DOI: https://doi.org/10.1038/ncpuro0729 SHARE THIS ARTICLE Anyone you share the following link with will be able to

read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative